Psychiatr. praxi. 2016;17(1):31-32 | DOI: 10.36290/psy.2016.009
Vortioxetine: a review of new antidepressant
- 1 Národní ústav duševního zdraví, Klecany
- 2 3. lékařská fakulta UK Praha
- 3 University of Texas Health Science Center at Houston, USA
Vortioxetine is a novel antidepressant with multimodal mechanism of action, acting as 5-HT3A, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1A agonist, 5-HT1B partial agonist, and serotonin transporter inhibitor. Antidepressant efficacy of vortioxetine 10–20 mg daily has been shown in the total of 13 acute short-term and 1 relapse-prevention controlled trials. Moreover, in 3 placebo-controlled trials vortioxetine improved cognitive functions, independent of antidepressive effects. Vortioxetine was well-tolerated, with low incidence of sexual dysfunction. Most frequently reported side effects were transient and dose-dependent nausea and vomiting. Initial and recommended therapeutic dose is 10 mg of vortioxetine once a day, the dosing range, according to response, tolerability, and age, is 5–20 mg daily.
Keywords: vortioxetine, depression, antidepressants, cognition
Published: March 1, 2016 Show citation
References
- Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21(9): 655-679.
Go to original source... 
Go to PubMed... - EMA, http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf (accessed December 23, 2015).
- Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145: 43-57. Go to original source...
- Mohr P, Anders M, Masopust J. Vortioxetin v léčbě depresivní poruchy a možnosti zlepšení kognitivních funkcí. Psychiatrie 2014; 18(4): 206-211.
- Connolly KR, Thase ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother 2016; 17(3): 421-431. Go to original source... Go to PubMed...
- Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014; 68(1): 60-82. Go to original source... Go to PubMed...
- Boulenger JP, Loft H, Florea I. Randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26(11): 1408-1416. Go to original source... Go to PubMed...
- Theunissen EL, Street D, H?jer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93(6): 493-501. Go to original source...
- Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27(4): 215-223. Go to original source... Go to PubMed...
- McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmaco. 2014; 17(10): 1557-1567. Go to original source... Go to PubMed...
- Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015; 40(8): 2025-2037. Go to original source... Go to PubMed...
- Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.CNS Spectr 2015; 12(10): 2036-2048.